Share Search
Visit the Share Search
You are here:
(Sharecast News) - Veterinary pharmaceuticals products manufacturer Eco Animal Health expects group revenues and underlying earnings for the year ending 31 March to be "significantly ahead" of both market expectations and the prior year.
Eco Animal said on Monday that continuing strength in the Chinese market, despite localised outbreaks of African swine fever, had led the group to record revenues in the Asian nation.
The AIM-listed group stated it had also delivered a strong performance in other territories, particularly in the USA.
Chief executive Marc Loomes said: "We are delighted that we will be trading ahead of market expectations and the current momentum that we are seeing in China with record revenues reflects the increasing demand for the group's flagship Aivlosin product line.
"We believe that our customers appreciate the superior performance of the group's products and we should not overlook the solid growth being experienced in most of the other geographical markets that ECO addresses."
As of 1135 GMT, Eco Animal shares were up 8.55% at 368.0p.
Eco Animal said on Monday that continuing strength in the Chinese market, despite localised outbreaks of African swine fever, had led the group to record revenues in the Asian nation.
The AIM-listed group stated it had also delivered a strong performance in other territories, particularly in the USA.
Chief executive Marc Loomes said: "We are delighted that we will be trading ahead of market expectations and the current momentum that we are seeing in China with record revenues reflects the increasing demand for the group's flagship Aivlosin product line.
"We believe that our customers appreciate the superior performance of the group's products and we should not overlook the solid growth being experienced in most of the other geographical markets that ECO addresses."
As of 1135 GMT, Eco Animal shares were up 8.55% at 368.0p.